Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia

Anand SS Yusuf S. ; for the Warfarin Antiplatelet Vascular Evaluation Trial Investigators, WAVE. Oral anticoagulants and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357: 217–227.

Bhatt DL Fox KAA Hacke W , et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706–1717.

Bonoca MP Bhatt DL Cohen M , et al.; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791–1800.

Hiatt WR Fowkes FGR Heizer G , et al.; for the EUCLID Trial Steering Committee and Investigators. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017; 376: 32–40.

Morrow DA Braunwald E Bonoca MP , et al.; TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404–1413.

Mega JL Braunwald E Wiviott SD , et al.; for the ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9–19.

Eikelboom JW Connolly SJ Bosch J , et al.; for the COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377: 1319–1330.

Anand SS Bosch J Eikelboom JW , et al.; on behalf of the COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 219–229.

Petersohn S Pouwels X Ramaekers B , et al. Rivaroxaban plus aspirin for the prevention of ischemic events in patients with cardiovascular disease: a cost-effectiveness study. Eur J Prev Cardiol, 2020; 27: 1354–1365.

Ichiki K Ikeda H Haramaki N , et al. Long-term smoking impairs platelet-derived nitric oxide release. Circulation 1996; 94: 3104–3114.

Nocella C Biondi-Zoccai G Sciarretta S , et al. Impact of tobacco versus electronic cigarette smoking on platelet function. Am J Cardiol 2018; 122: 1477–1481.

Swaminathan A Amitkumar K Ganapathy S , et al. Evaluation of the impact of cigarette smoking on platelet parameters. Natl J Physiol Pharm Pharmacol 2015; 5: 426–430.

Takajo Y Ikeda H Haramaki N , et al. Augmented oxidative stress of platelets in chronic smokers. Mechanisms of impaired platelet-derived nitric oxide bioactivity and augmented platelet aggregability. J Am Coll Cardiol 2001; 38: 1320–1327.

Kotseva K De Backer G De Bacquer D , et al. Primary prevention efforts are poorly developed in people at high cardiovascular risk: a report from the European Society of Cardiology EURObservational research Programme EUROASPIRE V survey in 16 European countries. Eur J Prev Cardiol, Epub ahead of print 20 March 2020. DOI: 10.1177/2047487320908698.

Kotseva K De Backer G De Bacquer D , et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol 2019; 26: 824–835.

De Smedt D De Backer T Petrivic M , et al. Chronic medication intake in patients with stable coronary heart disease across Europe: Evidence from the daily clinical practice. Results from the ESC EORP European Survey of Cardiovascular Disease Prevention and Diabetes (EUROASPIRE IV) Registry. Int J Cardiol 2020; 300: 7–13.

Rauch B Davos CH Doherty P , et al.; on behalf of the “Cardiac Rehabilitation Section”, European Association of Preventive Cardiology (EAPC). The prognostic effect of cardiac rehabilitation in the era of acute revascularization and statin therapy: a systematic review and meta-analysis of randomized and non-randomized studies – The Cardiac Rehabilitation Outcome Study (CROS). Eur J Prev Cardiol 2016; 23: 1914–1939.

Salzwedel A Jensen K Rauch B , et al. Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease patients treated according to contemporary evidence based medicine: update of the Cardiac Rehabilitation Outcome Study (CROS-II). Eur J Prev Cardiol. Epub ahead of print 23 February 2020. DOI: 10.1177/2047487320905719

Gysan D Millentrup S Albus C , et al. Substantial improvement of primary cardiovascular prevention by a systematic score-based multimodal approach: a randomized trial: the PreFord-Study. Eur J Prev Cardiol 2017; 24: 1544–1554.

Yang J Zheng Y Gou X , et al. Prevalence of comorbidities in the Novel Wuhan Coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis, Epub ahead of print 12 March 2020. DOI: 10.1016/j.ijid.2020.03.017.

Guo T Fan Y Chen M , et al. Cardiovascular implications of fatal outcomes of patients with Coronarvirus Disease 2019 (COVID-19). JAMA Cardiol, Epub ahead of print 27 March 2020. DOI: 10.1001/jamacardio.2020.1017.

Egan G Hughes CA Ackman ML. Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. Ann Pharmacother 2014; 48: 734–740.